-
公开(公告)号：US20140302061A1
公开(公告)日：2014-10-09
申请号：US14356029
申请日：2012-10-31
发明人： Maribel Beaumont , Jeanine D. Mattson , Jennifer R. Louten , Terrill K. McClanahan , Rene de Waal Malefyt
IPC分类号： C07K16/24 , G01N33/543
CPC分类号： C07K16/24 , C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , G01N33/54306 , G01N33/6863 , G01N2800/24 , G01N2800/52
摘要： The present invention relates to biomarker responsive to treatment with a TSLP antagonist.
摘要翻译： 本发明涉及响应于用TSLP拮抗剂治疗的生物标志物。
-
公开(公告)号：US20130287775A1
公开(公告)日：2013-10-31
申请号：US13925525
申请日：2013-06-24
发明人： Edward P. Bowman , Daniel J. Cua , Robert A. Kastelein , Kathy L. Miller , Melanie A. Kleinschek , Kristian S. Bak-Jensen , Katia Boniface , Brent S. McKenzie , Rene de Waal Malefyt
IPC分类号： A61K39/395
CPC分类号： A61K39/3955 , A61K31/55 , A61K31/5575 , A61K38/1793 , A61K39/395 , A61K45/06 , C07K16/244 , C07K2317/76 , A61K2300/00
摘要： Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.
摘要翻译： 提供了用于治疗诸如自身免疫性疾病或癌症的免疫疾病的方法和组合，涉及与抑制Th17细胞发育或维持的药物的联合治疗。 提供了治疗方案，其中施用促炎细胞因子的拮抗剂足以缓解自身免疫性疾病或癌症的急性期急性发作的体征和症状，并且用IL-23拮抗剂治疗是 持续较长时间，以防止急性事件复发。 还公开了PGE2和CD161的拮抗剂用于治疗自身免疫性，炎性和增殖性疾病。
-
公开(公告)号：US20140335094A1
公开(公告)日：2014-11-13
申请号：US14330909
申请日：2014-07-14
发明人： Birgit Oppmann , Rene de Waal Malefyt , Donna M. Rennick , Robert A. Kastelein , Maria T. Wiekowski , Sergio A. Lira , Satwant K. Narula
IPC分类号： C07K16/24
CPC分类号： C07K16/244 , A01K2217/05 , A61K38/00 , C07K14/54 , C07K14/5434 , C07K2317/32 , C07K2319/00 , C07K2319/02 , Y10S530/827
摘要： Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
摘要翻译： 提供了编码哺乳动物细胞因子的纯化基因，与其相关的试剂，包括纯化蛋白质，特异性抗体和编码该分子的核酸。 还提供了使用所述试剂和诊断试剂盒的方法。
-
公开(公告)号：US09732151B2
公开(公告)日：2017-08-15
申请号：US14356029
申请日：2012-10-31
发明人： Maribel Beaumont , Jeanine D. Mattson , Jennifer R. Louten , Terrill K. McClanahan , Rene de Waal Malefyt
IPC分类号： C07K16/24 , G01N33/543 , G01N33/68 , C12Q1/68
CPC分类号： C07K16/24 , C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , G01N33/54306 , G01N33/6863 , G01N2800/24 , G01N2800/52
摘要： The present invention relates to biomarker responsive to treatment with an anti-Thymic Stromal Lymphopoietin (TSLP) antibody.
-
5.发明申请公开(公告)号：US20140093875A1
公开(公告)日：2014-04-03
申请号：US14094511
申请日：2013-12-02
发明人： Pedro A. Reche-Gallardo , Vassili Soumelis , Yong-Jun Liu , Rene de Waal Malefyt , J. Fernando Bazan , Robert A. Kastelein
IPC分类号： C07K16/24 , G01N33/68 , C07K14/715
CPC分类号： C07K16/244 , C07K14/54 , C07K14/7155 , G01N33/6863 , G01N33/6869 , G01N2333/54 , G01N2500/02
摘要： Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
摘要翻译： 编码哺乳动物细胞因子受体的核酸，例如细胞因子IL-B50，纯化的蛋白质及其片段。 还提供了抗体，包括多克隆和单克隆抗体。 描述了用于诊断和治疗用途的组合物的方法。
-
公开(公告)号：US20210363243A1
公开(公告)日：2021-11-25
申请号：US16966100
申请日：2019-01-31
发明人： Mingmei Cai , Rene de Waal Malefyt , Laurence Fayadat-Dilman , Ying Li , Ruban Mangadu , Uyen Phan
摘要： Provided herein are methods of treating cancer or infection, which comprise administering to a human patient in need thereof: (a) an anti-human PD-1 monoclonal antibody or antigen binding fragment thereof; (b) an anti-human LAG3 monoclonal antibody or antigen binding fragment thereof; and (c) an anti-human TIGIT monoclonal antibody or antigen binding fragment thereof. Also provided are pharmaceutical compositions and kits containing such agents for the treatment of cancer or infection.
-
公开(公告)号：US20190270802A1
公开(公告)日：2019-09-05
申请号：US16342283
申请日：2017-10-19
摘要： The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and an antagonist of IL-27, and the use of the combination therapies for the treatment of cancer. In certain embodiments, the PD-1 antagonist is an anti-human PD-1 antibody, or antigen binding fragment thereof. In further embodiments, the anti-PD-1 antibody is pembrolizumab. In certain embodiments the antagonist of IL-27 is an anti-IL-27 antibody, or antigen binding fragment thereof, an anti-p28 antibody, or antigen binding fragment thereof, or an anti-EBI-3 antibody, or antigen binding fragment thereof. Also provided are medicaments, compositions, and kits comprising a PD-1 antagonist and an IL-27 antagonist for use in treating cancer.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.019 秒)
